Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 5, 2015, Pages 1571-1576

  Poruchynsky, Marianne S ^a   Komlodi Pasztor, Edina ^a   Trostel, Shana ^a   Wilkerson, Julia ^a   Regairaz, Marie ^a,c   Pommierb, Yves ^a   Zhang, Xu ^a   Maity, Tapan Kumar ^a   Robey, Robert ^a   Burotto, Mauricio ^a   Sackettc, Dan ^b   Guha, Udayan ^a   Fojo, Antonio Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Combination chemotherapy,targeted therapies; Dna repair protein trafficking; DNA damaging agents; Microtubule targeting agents

Indexed keywords

ATM PROTEIN; ATR PROTEIN; DEOXYRIBONUCLEOPROTEIN; DNA PK PROTEIN; DOXORUBICIN; DYNEIN ADENOSINE TRIPHOSPHATASE; ETOPOSIDE; HISTONE H2AX; MRE11 PROTEIN; NIBRIN; PACLITAXEL; PROTEIN P53; PROTEIN P63; RAD50 PROTEIN; TOZASERTIB; TUBULIN; UNCLASSIFIED DRUG; VINCRISTINE; DNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL CYCLE ARREST; CELL DISRUPTION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; MICROTUBULE; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA; DNA DAMAGE; DNA REPAIR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICROTUBULES;

EID: 84922236597     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1416418112     Document Type: Article

References (39)

1. Milas L, et al. (1995) Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 35(4):297-303.
2. Horton JK, Houghton PJ, Houghton JA (1988) Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol 37(20):3995-4000.
3. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T (2011) Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 8(4):244-250.
4. Komlodi-Pasztor E, Sackett DL, Fojo AT (2012) Inhibitors targeting mitosis: Tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 18(1):51-63.
5. Mitchison TJ (2012) The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 23(1):1-6.
6. Shin J-S, et al. (2008) Serum starvation induces G1 arrest through suppression of Skp2-CDK2 and CDK4 in SK-OV-3 cells. Int J Oncol 32(2):435-439.
7. Jordan MA, Horwitz SB, Lobert S, Correia JJ (2008) Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine. Semin Oncol 35(3, Suppl 3):S6-S12.
8. Oroudjev E, et al. (2010) Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 9(10):2700-2713.
9. Yang CP, Liu L, Ikui AE, Horwitz SB (2010) The interaction between mitotic checkpoint proteins, CENP-E and BubR1, is diminished in epothilone B-resistant A549 cells. Cell Cycle 9(6):1207-1213.
10. Gan PP, et al. (2010) Microtubule dynamics, mitotic arrest, and apoptosis: Druginduced differential effects of betaIII-tubulin. Mol Cancer Ther 9(5):1339-1348.
11. Rovini A, Savry A, Braguer D, Carré M (2011) Microtubule-targeted agents: When mitochondria become essential to chemotherapy. Biochim Biophys Acta 1807(6): 679-688.
12. Hage-Sleiman R, Herveau S, Matera EL, Laurier JF, Dumontet C (2011) Silencing of tubulin binding cofactor C modifies microtubule dynamics and cell cycle distribution and enhances sensitivity to gemcitabine in breast cancer cells. Mol Cancer Ther 10(2): 303-312.
13. de Bono JS, et al.; TROPIC Investigators (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376(9747):1147-1154.
14. Tannock IF, et al.; TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502-1512.
15. Gulley JL, et al. (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59(5):663-674.
16. Popiolek M, et al. (2013) Natural history of early, localized prostate cancer: A final report from three decades of follow-up. Eur Urol 63(3):428-435.
17. Eichholz A, Ferraldeschi R, Attard G, de Bono JS (2012) Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol 360(1-2):68-75.
18. Darshan MS, et al. (2011) Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 71(18):6019-6029.
19. Zhu M-L, et al. (2010) Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70(20):7992-8002.
20. de Bono JS, et al.; COU-AA-301 Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995-2005.
21. Ryan CJ, et al.; COU-AA-302 Investigators (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138-148.
22. Scher HI, et al.; AFFIRM Investigators (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187-1197.
23. Giannakakou P, et al. (2002) Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA 99(16):10855-10860.
24. Jang CY, Kim HD, Zhang X, Chang JS, Kim J (2012) Ribosomal protein S3 localizes on the mitotic spindle and functions as a microtubule associated protein in mitosis. Biochem Biophys Res Commun 429(1-2):57-62.
25. Suárez-Sánchez R, et al. (2014) Nucleocytoplasmic shuttling of the Duchenne muscular dystrophy gene product dystrophin Dp71d is dependent on the importin α/β and CRM1 nuclear transporters and microtubule motor dynein. Biochim Biophys Acta 1843(5):985-1001.
26. Belanto JJ, et al. (2014) Microtubule binding distinguishes dystrophin from utrophin. Proc Natl Acad Sci USA 111(15):5723-5728.
27. Thadani-Mulero M, Nanus DM, Giannakakou P (2012) Androgen receptor on the move: Boarding the microtubule expressway to the nucleus. Cancer Res 72(18): 4611-4615.
28. Trostel SY, Sackett DL, Fojo T (2006) Oligomerization of p53 precedes its association with dynein and nuclear accumulation. Cell Cycle 5(19):2253-2259.
29. Kinner A, Wu W, Staudt C, Iliakis G (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36(17): 5678-5694.
30. Solier S, Pommier Y (2014) The nuclear γ-H2AX apoptotic ring: Implications for cancers and autoimmune diseases. Cell Mol Life Sci 71(12):2289-2297.
31. Gupta A, et al. (2014) Role of 53BP1 in the regulation of DNA double-strand break repair pathway choice. Radiat Res 181(1):1-8.
32. Tanaka T, et al. (2007) Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A 71(9):648-661.
33. Forrest RA, et al. (2012) Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation. Biochem Pharmacol 83(12):1602-1612.
34. Mould E, et al. (2014) Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity. Biochem Pharmacol 88(1):58-65.
35. Huff LM, Sackett DL, Poruchynsky MS, Fojo T (2010) Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Res 70(14):5870-5879.
36. Murphy RF, et al. (2012) Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. Cell Cycle 11(5):963-973.
37. Li PK, et al. (2006) A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther 5(2):450-456.
38. Poruchynsky MS, et al. (2008) Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 7(7):940-949.
39. Guha U, et al. (2008) Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA 105(37):14112-14117.